Indaptus Therapeutics (NASDAQ:INDP – Get Rating) and Q BioMed (OTCMKTS:QBIO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Valuation and Earnings
This table compares Indaptus Therapeutics and Q BioMed’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Indaptus Therapeutics||N/A||N/A||-$7.71 million||N/A||N/A|
|Q BioMed||$200,000.00||19.22||-$8.24 million||($0.31)||-0.35|
Risk and Volatility
Indaptus Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Q BioMed has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.
Insider and Institutional Ownership
22.3% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Q BioMed shares are held by institutional investors. 3.3% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Indaptus Therapeutics and Q BioMed’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for Indaptus Therapeutics and Q BioMed, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Indaptus Therapeutics currently has a consensus price target of $15.50, suggesting a potential upside of 525.00%. Given Indaptus Therapeutics’ higher possible upside, equities analysts plainly believe Indaptus Therapeutics is more favorable than Q BioMed.
Indaptus Therapeutics beats Q BioMed on 7 of the 10 factors compared between the two stocks.
Indaptus Therapeutics Company Profile (Get Rating)
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Q BioMed Company Profile (Get Rating)
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.